Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
279.2 SEK | -0.64% | -0.85% | +5.09% |
Sales 2024 * | 24.57B 2.33B | Sales 2025 * | 27.25B 2.58B | Capitalization | 95.5B 9.05B |
---|---|---|---|---|---|
Net income 2024 * | 3.41B 323M | Net income 2025 * | 4.99B 472M | EV / Sales 2024 * | 4.48 x |
Net Debt 2024 * | 14.46B 1.37B | Net Debt 2025 * | 8.87B 840M | EV / Sales 2025 * | 3.83 x |
P/E ratio 2024 * |
28.1
x | P/E ratio 2025 * |
19.3
x | Employees | 1,752 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 50.9% |
Latest transcript on Swedish Orphan Biovitrum AB
1 day | -2.63% | ||
1 week | -0.50% | ||
Current month | -0.50% | ||
1 month | -0.92% | ||
3 months | +0.07% | ||
6 months | +17.38% | ||
Current year | +5.24% |
Managers | Title | Age | Since |
---|---|---|---|
Guido Oelkers
CEO | Chief Executive Officer | 59 | 17-05-21 |
Henrik Stenqvist
DFI | Director of Finance/CFO | 57 | 18-07-19 |
Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 68 | 20-12-31 | |
Annette Clancy
CHM | Chairman | 70 | 14-05-07 |
Staffan Schüberg
BRD | Director/Board Member | 55 | 19-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.15% | 262 M€ | +13.30% | ||
0.90% | 4 M€ | +15.27% | ||
0.69% | 142 M€ | +11.55% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-10 | 280.6 | -0.14% | 18 372 |
24-06-07 | 281 | -2.63% | 514,506 |
24-06-05 | 288.6 | +1.48% | 204,033 |
24-06-04 | 284.4 | +0.49% | 385,214 |
24-06-03 | 283 | +0.21% | 301,264 |
Delayed Quote Nasdaq Stockholm, June 07, 2024 at 11:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.24% | 9.06B | |
+0.82% | 91.94B | |
-1.32% | 38.74B | |
-12.88% | 32.82B | |
+64.77% | 26.66B | |
-16.31% | 15.32B | |
-11.38% | 11.65B | |
+173.10% | 10.37B | |
-49.84% | 10.12B | |
-16.26% | 7.46B |
- Stock Market
- Equities
- SOBI Stock